- Home
- REBN vs NEUP Comparison
REBN vs NEUP Comparison
Compare REBN & NEUP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- REBN
- NEUP
- Stock Information
- Founded
- REBN 2015
- NEUP 1996
- Country
- REBN United States
- NEUP United States
- Employees
- REBN N/A
- NEUP N/A
- Industry
- REBN Restaurants
- NEUP
- Sector
- REBN Consumer Discretionary
- NEUP
- Exchange
- REBN Nasdaq
- NEUP Nasdaq
- Market Cap
- REBN 15.3M
- NEUP 12.7M
- IPO Year
- REBN 2022
- NEUP N/A
- Fundamental
- Price
- REBN $2.52
- NEUP $9.55
- Analyst Decision
- REBN
- NEUP Strong Buy
- Analyst Count
- REBN 0
- NEUP 2
- Target Price
- REBN N/A
- NEUP $28.00
- AVG Volume (30 Days)
- REBN 89.9K
- NEUP 83.7K
- Earning Date
- REBN 08-14-2025
- NEUP 11-15-2025
- Dividend Yield
- REBN N/A
- NEUP N/A
- EPS Growth
- REBN N/A
- NEUP N/A
- EPS
- REBN N/A
- NEUP 0.00
- Revenue
- REBN $6,565,623.00
- NEUP $15,662,715.00
- Revenue This Year
- REBN $335.98
- NEUP N/A
- Revenue Next Year
- REBN N/A
- NEUP N/A
- P/E Ratio
- REBN N/A
- NEUP $6,374.34
- Revenue Growth
- REBN 14.03
- NEUP N/A
- 52 Week Low
- REBN $1.03
- NEUP $2.90
- 52 Week High
- REBN $8.30
- NEUP $126.00
- Technical
- Relative Strength Index (RSI)
- REBN 44.40
- NEUP 44.06
- Support Level
- REBN $2.33
- NEUP $11.42
- Resistance Level
- REBN $2.89
- NEUP $15.14
- Average True Range (ATR)
- REBN 0.18
- NEUP 1.62
- MACD
- REBN 0.01
- NEUP -0.37
- Stochastic Oscillator
- REBN 36.25
- NEUP 4.52
About REBN Reborn Coffee Inc.
Reborn Coffee Inc is an operator and franchisor of retail locations and kiosks that focus on serving specialty-roasted coffee. It is an company that strives for constant improvement in the coffee experience through exploration of new technology and premier service, guided by traditional brewing techniques. The company operates in one reportable segment, consisting of both the wholesale and retail sales of coffee, water, and other beverages.
About NEUP Neuphoria Therapeutics Inc. Common Stock
Neuphoria Therapeutics Inc is a clinical stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. The company is advancing its drug candidate, BNC 210, an oral, proprietary, selective negative allosteric modulator of the Alpha7 nicotinic acetylcholine receptor, for the acute treatment of social anxiety disorder and for chronic treatment of post-traumatic stress disorder.